Meloxicam Market Analysis

Diseases (Osteoarthritis, Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis)

In terms of disease, the osteoarthritis segment in the meloxicam market is estimated to account for the largest revenue share of 40% by the end of 2036. The rise in prevalence and consumer awareness of treatment options like glucosamine and chondroitin sulfate, which do not significantly reduce the signs of this medical condition but instead assist in preserving joint motion over an extended period of time, can be attributed to the growth of this market in the projected time period. A severe health emergency also includes arthritis.  According to the CDC, 53.2 million US individuals, or 1 in 4, have some kind of arthritis. There are more than 100 different forms of arthritis, but osteoarthritis, which affects 32.5 million US adults, is the most widespread.

Drug Type (Combination Drug, Prescribed Drug)

Meloxicam market from the combination drug segment is set to grow significantly by 2036. Combination drugs are drugs taken together to treat different conditions, and their ability to treat many diseases is the main reason for this increase in demand. For example, Vioxx is a combination drug used to treat both rheumatoid arthritis and pain; however, it caused heart problems as well as other side effects and thus fell behind in the market.

Our in-depth analysis of the global meloxicam market includes the following segments: